Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 4/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | GCK | P35557 | 3/20 | 0.32 |
| ▸ | CTSL | P07711 | 2/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6908374 | 0.92 | CTSK (0.36) | CTSKCTSLIDO1 | |
| SCHEMBL13641977 | 0.90 | CTSK (0.35) | CTSKKDM4EALDH1A1LMNAHTT | |
| SCHEMBL13584567 | 0.90 | CTSK (0.35) | CTSKKDM4EALDH1A1LMNAHTT | |
| SCHEMBL13584641 | 0.88 | CTSK (0.34) | CTSKKDM4EALDH1A1LMNAHTT | |
| SCHEMBL6886050 | 0.88 | CTSK (0.34) | CTSKKDM4EALDH1A1LMNAHTT | |
| SCHEMBL6908637 | 0.85 | CTSK (0.41) | CTSKKDM4EALDH1A1LMNAHTT | |
| SCHEMBL14325523 | 0.85 | CTSK (0.46) | CTSKKDM4EALDH1A1LMNAHTT | |
| SCHEMBL14317256 | 0.84 | CTSK (0.36) | CTSKCTSLCTSS | |
| SCHEMBL6886347 | 0.84 | CTSK (0.36) | CTSKCTSLCTSS | |
| SCHEMBL14248857 | 0.83 | CTSK (0.37) | CTSKKDM4EALDH1A1LMNAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8815809-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-08-26 | — | — | US | disclosed |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-06 | — | — | US | disclosed |
| WO-2011070539-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | CTSK 13/4885KDM4E 4154/4885ALDH1A1 2532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.